CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 2:15 p.m. ET.
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the company’s Investors "Events & Presentations" page. A replay will be archived for 14 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRSP
In the Apr 7 session, CRSP gained 1.12%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- April 13
- Needham Virtual Healthcare Conference presentation date
- Presentation time
- 2:15 p.m. ET
- Scheduled time for fireside chat webcast
- Webcast replay period
- 14 days
- Replay availability on company website after presentation
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference edition
Historical Context
-
Upsized $550M 2031 convertible notes pricing with added $50M option.
-
Announcement of proposed $350M 2031 convertible senior notes financing.
-
Q4/FY 2025 results with CASGEVY revenue and broad pipeline progress.
-
Outlined 2026 milestones, cash of ~$2B, and CASGEVY >$100M revenue.
-
J.P. Morgan Healthcare Conference presentation and webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, Apr 13 at 2:15 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.